The first of three studies from the Patented Medicine Prices Review Board to compare drug coverage across provincial and federal public drug plans looks at overlap for 729 drugs that represented 82% of public drug costs in 2015. It finds that individual public plans listed close to four-fifths of the selected drugs, with the remainder only accounting for 5% of the overall costs. Furthermore, 92% of the 125 medicines deemed essential were also covered by all public plans, while those drugs with available generics had a listing rate of 86%. Parts two and three of the series will focus on newer non-cancer drugs evaluated for their cost-effectiveness via the Common Drug Review (CDR) and cancer drugs evaluated via the pan-Canadian Oncology Drug Review (p-CODR).
Autres nouvelles:
Une étude révèle un important chevauchement des médicaments couverts par les régimes publics d'assurance-médicaments canadien - Conseil d'examen du prix des médicaments brevetés
Viabilité